CompletedPhase 2NCT02244606
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Studying Invasive candidiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Scynexis, Inc.
- Principal Investigator
- David Angulo, MDScynexis, Inc.
- Intervention
- SCY-078(drug)
- Enrollment
- 27 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2016
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UC Davis Medical Center, Sacramento, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- University of Miami, Miami, Florida, United States
- Georgia Regents University, Augusta, Georgia, United States
- University of Chicago, Chicago, Illinois, United States
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Mercury Street Medical Group, Butte, Montana, United States
- Albany Medical Center, Albany, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02244606 on ClinicalTrials.govOther trials for Invasive candidiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05421858A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Basilea Pharmaceutica
- RECRUITINGPHASE2NCT06194201A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisFujian Shengdi Pharmaceutical Co., Ltd.
- RECRUITINGNCT06456151Invasive Candidiasis in Critical CareUniversity Hospital Ostrava
- RECRUITINGNANCT05763251Comparison of Uncomplicated Candidemia Therapy Duration in ChildrenArkansas Children's Hospital Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04368559Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationMundipharma Research Limited
- RECRUITINGNANCT03538912Early Discontinuation of Empirical Antifungal Therapy and BiomarkersUniversity Hospital, Lille